<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="in animal models. As various models for SARS-CoV-2 are under" exact="testing" post="phase, biotech companies have bypassed animal studies and moved"/>
 <result pre="and transmission dynamics that make them ideal models for vaccine" exact="testing" post="for COVID-19. Another issue of using animal model is"/>
 <result pre="transmission rates from humans to humans is still ambiguous. For" exact="infection" post="into human cells, the receptor-binding domain of spike protein"/>
 <result pre="to be, for now, several folds higher (Rosenbaum 2020). The" exact="infection" post="has advanced to more than 210 countries and territories"/>
 <result pre="USA, and an antimalarial drug, chloroquine (CQ)/hydroxychloroquine (HCQ), for the" exact="treatment" post="of COVID-19.Â An array of drugs approved for other"/>
 <result pre="an antimalarial, is currently being considered as a part of" exact="treatment" post="strategy against COVID-19 (Colson et al.2020). CQ has also"/>
 <result pre="show only limited effects of CQ/HCQ or HCQ-azithromycin combination on" exact="treatment" post="for COVID-19. Since CQ/HCQ is known to cause toxic"/>
 <result pre="the virus to gain resistance against these drugs. Further animal" exact="testing" post="will also be important to measure absorbance of the"/>
 <result pre="elevate endosomal pH and interfere with ACE2 glycosylation Material parasite" exact="infection" post="Â 192725-17-0 Â 155213-67-3 Lopinavir Ritonavir 3CLpro &amp;amp; PLpro-"/>
 <result pre="protease: 3CLpro or PLpro Used in combination for HIV virus" exact="treatment" post="Â 1809249-37-3 Remdesivir Act as nucleotide analogue A nucleotide"/>
 <result pre="block viral nucleotide synthesis to stop viral replication Ebola virus" exact="infection" post="Â 145258-61-3 Interferon beta-1a (used in combination with Lopinavir"/>
 <result pre="of the virus. In principle, drugs only help in the" exact="treatment" post="of humans once they contract the disease, but for"/>
 <result pre="Thereafter, this candidate is challenged for its vaccine potential by" exact="testing" post="it in animal models for the disease where the"/>
 <result pre="disease, duration of induced protection, the host immune response to" exact="infection" post="and vaccination (Griffin 2002). Thus, testing in animals is"/>
 <result pre="host immune response to infection and vaccination (Griffin 2002). Thus," exact="testing" post="in animals is considered to be an important and"/>
 <result pre="most of the animal disease models for SARS-CoV-2 are under" exact="testing" post="and, in the absence of these models, it is"/>
 <result pre="models that are being tested based on their pathogenesis after" exact="infection" post="with SARS-CoV-2. Rhesus macaques As the key 12 amino"/>
 <result pre="humans, and hence the choice for animal studies for vaccine" exact="testing" post="of COVID-19. The studies with macaques have shown that"/>
 <result pre="in rhesus macaques matches with the milder symptoms of SARS-CoV-2" exact="infection" post="in humans. Further, serum analysis demonstrate an increase in"/>
 <result pre="lethal brain disease, making it an obvious choice to test" exact="infection" post="with SARS-CoV-2 as well. However, due to lack of"/>
 <result pre="from China have shown that hACE2 mice do support SARS-CoV-2" exact="infection" post="where they reduce weight by 20% and virus replication"/>
 <result pre="SARS-CoV-2 (Bao et al.2020). Syrian hamster These animals support SARS" exact="infection" post="and show maximum similarity to human ACE2, where only"/>
 <result pre="ACE2, making them a testable model for SARS-CoV-2 infection. Upon" exact="infection" post="of SARS-CoV-2, Syrian hamsters demonstrate weight loss by ~11%"/>
 <result pre="and necrosis of alveolae damage is visible during the initial" exact="infection" post="period. The inflammation of intestinal mucosal epithelium that is"/>
 <result pre="vaccine studies. Thus, there are many promising animal models for" exact="testing" post="the vaccine candidates for SARS-CoV-2, but still extensive studies"/>
 <result pre="an appropriate model for COVID-19. In order to fight coronavirus" exact="infection" post="and win the race against time, Moderna, a biotechnological"/>
 <result pre="Phase I clinical trial with experimental vaccine mRNA-1273 (â€˜RNA vaccine" exact="testing" post="beginsâ€™ 2020, WHO 2020b). Their argument for directly going"/>
 <result pre="both in terms of toxicity and challenge studies. Isuprel, a" exact="treatment" post="for asthma, was rendered safe in rats, guinea pigs,"/>
 <result pre="Although cell lines can also be used to study the" exact="infection" post="process, animal models provide the advantage of studying the"/>
 <result pre="to FcÎ³ receptor on circulating monocytes, resulting in the efficient" exact="infection" post="of monocytes by the virus (Halstead 2002). Thus, instead"/>
 <result pre="higher complications and death of the subject in case of" exact="infection" post="by the pathogen (Huisman et al.2009). Therefore, the biotech"/>
 <result pre="However, challenge of these cats results in enhanced susceptibility to" exact="infection" post="along with death of cats (Huisman et al.2009). This"/>
 <result pre="this global emergency, the entire scientific community is attempting effective" exact="treatment" post="and prevention of the disease. To shorten the time"/>
 <result pre="success, effective and targeted drugs and vaccines for the SARS-CoV-2" exact="infection" post="are still awaited. Moreover, agencies like WHO and FDA"/>
 <result pre="animal model is one of the main concerns for animal" exact="testing" post="as the animal should mimic the response and effects"/>
 <result pre="supplyNature202057918310.1038/d41586-020-00698-x CameronMJKelvinAALeonAJCameronCMRanLXuLChuYDaneshAet al.Lack of innate interferon responses during SARS coronavirus" exact="infection" post="in a vaccination and reinfection ferret modelPLoS One201210.1371/journal.pone.0045842 CaoBWangYWenDLiuWWangJFanGRuanLSongBet"/>
 <result pre="(SARS-CoV-2): Facts and mythsJ. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.02.012 LiangKMathematical model of" exact="infection" post="kinetics and its analysis for COVID-19SARS and MERS. Infect."/>
 <result pre="al.Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusionAutophagy2018141435145510.1080/15548627.2018.147431429940786 McCrayPBPeweLWohlford-LenaneCHickeyMManzelLShiLNetlandJJiaHPet al.Lethal" exact="infection" post="of K18-hACE2 mice infected with severe acute respiratory syndrome"/>
 <result pre="the epidemicâ€™s front lineN Engl J Med.20203821873187510.1056/NEJMp200549232187459 collab: RNA vaccine" exact="testing" post="beginsDispatches from the COVID-19 crisisScience20203671284128610.1126/science.367.6484.128432193298 SavarinoAGenneroLSperberKBoelaertJRThe anti-HIV-1 activity of"/>
</results>
